Barth Syndrome Foundation Logo
BOSTON (PRWEB) August 24, 2020
Barth Syndrome Foundation (BSF) and American Heart Association (AHA) have announced a first-ever partnership to advance research studying cardiac complications associated with Barth syndrome, a rare, life-threatening, mitochondrial disease. Structured as a fellowship, the partnership aims to also address a severe shortage of early-career researchers by incentivizing a focus on a rare indication. This important collaboration between the AHA and BSF marks a strategic shift by BSF to broaden its impact by joining forces to accelerate progress through science and education.
Barth syndrome is a rare, X-linked, inborn error of metabolism characterized by cardiomyopathy, cardiolipin deficiency, musculoskeletal weakness, neutropenia, debilitating fatigue, growth delay, and hypoglycemia, among other clinical manifestations. The disease most commonly affects boys and is associated with a genetic mutation in the TAZ gene (tafazzin) causing abnormal cardiolipin remodeling and impaired mitochondrial structure. As a result, over 70% of Barth syndrome patients present with cardiac complications. Specifically, dilated or hypertrophic cardiomyopathy, and left ventricular non-compaction contribute to heightened mortality and morbidity in the first year of life. 17% of patients with Barth syndrome ultimately receive a heart transplant due to cardiac failure, and 13% are treated with internal pacemaker devices due to life-threatening arrhythmias.
The AHA/BSF fellowship provides a research opportunity for an investigator to explore the underlying pathology of the cardiac abnormalities present in Barth syndrome and other diseases. Supporting young promising researchers is an investment in both our research challenges now and scientific needs for the future. In partnering with the AHA, BSF is embarking on a model of engaging fellow philanthropic and institutional partners to address common scientific and clinical challenges that ultimately benefit all of our patient communities, says BSFs Director of Research Erik Lontok PhD. Since its founding in 2000, BSF has awarded $5.4 million dollars towards Barth syndrome research, which in turn has translated into $30.7 million dollars in follow-on funding. Collaboration is a central tenet of our research program, and our effort with AHA serves as a template and an opportunity to mutually advance common research and clinical challenges with diseases that share a phenotypic overlap with Barth syndrome.
Although Barth syndrome is an ultra-rare disease affecting around 250 known, living individuals worldwide, its multi-system and organ manifestations share many symptoms with other diseases and conditions. This partnership represents expansion of BSFs portfolio targeting one organ system, with additional strategic partnerships with neuromuscular, metabolic, and immunocompromised disease groups anticipated in the near future.
ABOUT BARTH SYNDROME FOUNDATION Barth Syndrome Foundation is the only global network of families, healthcare providers, and researchers solely driven by the mission to save lives through education, advances in treatment and finding a cure for Barth syndrome. BSF has funded nearly $5.4M USD since 2000 and catalyzed over $30.7M USD in funding from other agencies to advance global scientific discoveries to end the suffering and loss of life from Barth syndrome. Additionally, BSF provides a lifeline to families and individuals living with Barth syndrome around the world, offering 24/7 individualized support, educational conferences, a patient registry, as well as collaborations with specialist healthcare providers to define standards of care, treatment and rapid diagnosis.
Share article on social media or email:
Continue reading here:
American Heart Association and Barth Syndrome Foundation Partner to Address Rare Disease - PR Web
- Managing Right Ventricular Failure in PAH: An Algorithmic Approach | Advances in ... [Last Updated On: April 13th, 2018] [Originally Added On: April 13th, 2018]
- What Is the Ejection Fraction? - Verywell Health [Last Updated On: May 12th, 2018] [Originally Added On: May 12th, 2018]
- Ventricular septal defect - Wikipedia [Last Updated On: June 21st, 2018] [Originally Added On: June 21st, 2018]
- Heart Failure Medication: Beta-Blockers, Alpha Activity ... [Last Updated On: July 7th, 2018] [Originally Added On: July 7th, 2018]
- Acute Management of Pulmonary Embolism - American College ... [Last Updated On: July 17th, 2018] [Originally Added On: July 17th, 2018]
- Ventricular Remodeling | Profiles RNS [Last Updated On: July 24th, 2018] [Originally Added On: July 24th, 2018]
- Left ventricular hypertrophy - Wikipedia [Last Updated On: August 20th, 2018] [Originally Added On: August 20th, 2018]
- Ventricular Remodeling Surgery (SVR) [Last Updated On: September 24th, 2018] [Originally Added On: September 24th, 2018]
- Left Ventricular Remodeling in Heart Failure | JACC ... [Last Updated On: November 25th, 2018] [Originally Added On: November 25th, 2018]
- Ventricular dysfunction in heart failure - Britannica.com [Last Updated On: December 25th, 2018] [Originally Added On: December 25th, 2018]
- TIMI Study Group - LEADERSHIP [Last Updated On: January 31st, 2019] [Originally Added On: January 31st, 2019]
- Ventricular Remodeling Procedure | Main Line Health ... [Last Updated On: February 24th, 2019] [Originally Added On: February 24th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS) - Stocks Beat [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Reviewing Aeterna Zentaris Inc. (AEZS)'s and BioLineRx Ltd. (NASDAQ:BLRX)'s results - Stocks Beat [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Karuna Therapeutics Inc. (KRTX) and BioLineRx Ltd. (NASDAQ:BLRX) Comparing side by side - Stocks Beat [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Arbutus Biopharma Corporation (ABUS)'s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX) - The EN Herald [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Cardiac Dimensions touts Carillon TMVR study - Mass Device [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF - TCTMD [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Cardiac Restoration Systems Market Will Make a Huge Impact in Near Future - Wolf Mirror [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Reduce Fmr Study Shows Cardiac Dimensions' Carillon System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure - TCTMD [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Heart Failure Society of America 2019: Virtual Visits, Spironolactone Issues, and Reasons to Worry - DocWire News [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- LV Reverse Remodeling Not Improved by SGLT-2 Inhibitor - DocWire News [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Soligenix Inc. (NASDAQ:SNGX) - CryptoCoinsTribune [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) Could Burn Your Long Portfolio After More Shorts - The MAK Daily [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Reviewing BioLineRx Ltd. (BLRX)'s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)'s results - CryptoCoinsTribune [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Comparison of Protalix BioTherapeutics Inc. (PLX) and BioLineRx Ltd. (NASDAQ:BLRX) - MS Wkly [Last Updated On: October 19th, 2019] [Originally Added On: October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Edge Therapeutics Inc. (:) - MS Wkly [Last Updated On: October 19th, 2019] [Originally Added On: October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) - The Broch Herald [Last Updated On: November 7th, 2019] [Originally Added On: November 7th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Cyanotech Corporation (NASDAQ:CYAN) - The Broch Herald [Last Updated On: November 7th, 2019] [Originally Added On: November 7th, 2019]
- Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for... [Last Updated On: November 7th, 2019] [Originally Added On: November 7th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) - The Broch Herald [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT - Yahoo Finance [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- Cardiac Restoration Systems Market: Key Growth Factors and Industry Analysis 2018 - 2028 - The Market Expedition [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- Velocity Transfer Function In The Right Pulmonary Artery And Impaired | COPD - Dove Medical Press [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- 3 Stocks to Buy Ahead of the Next Market Crash - The Motley Fool [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival - TCTMD [Last Updated On: December 3rd, 2019] [Originally Added On: December 3rd, 2019]
- Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy - AJMC.com Managed Markets Network [Last Updated On: December 4th, 2019] [Originally Added On: December 4th, 2019]
- BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System - Yahoo Finance [Last Updated On: December 4th, 2019] [Originally Added On: December 4th, 2019]
- Cardiac Restoration Systems Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2055 2017 2025 - Weekly News Times [Last Updated On: December 13th, 2019] [Originally Added On: December 13th, 2019]
- The Outer Line: The impact of endurance training on the cardiac health of women - VeloNews [Last Updated On: December 13th, 2019] [Originally Added On: December 13th, 2019]
- Contrasting of Insmed Incorporated (INSM) and BioLineRx Ltd. (NASDAQ:BLRX) - The CoinGlobalist [Last Updated On: December 16th, 2019] [Originally Added On: December 16th, 2019]
- CARDIAC RESTORATION SYSTEMS MARKET ANALYSIS TRENDS, GROWTH OPPORTUNITIES, SIZE, TYPE, DYNAMIC DEMAND AND DRIVES WITH FORECASTS TO 2028 - Voice of... [Last Updated On: January 13th, 2020] [Originally Added On: January 13th, 2020]
- Early Expressed Circulating Long Noncoding RNA CHAST is Associated with Cardiac Contractile Function in Patients with Acute Myocardial Infarction -... [Last Updated On: January 13th, 2020] [Originally Added On: January 13th, 2020]
- Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone - DocWire News [Last Updated On: January 23rd, 2020] [Originally Added On: January 23rd, 2020]
- Increased Long-Term Risk for Venous Thromboembolism After Heart Failure - The Cardiology Advisor [Last Updated On: January 23rd, 2020] [Originally Added On: January 23rd, 2020]
- Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity - Science Advances [Last Updated On: February 1st, 2020] [Originally Added On: February 1st, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - The Cardiology Advisor [Last Updated On: February 1st, 2020] [Originally Added On: February 1st, 2020]
- New Data Confirms Cardiac Dimensions' Carillon System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation -... [Last Updated On: February 26th, 2020] [Originally Added On: February 26th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Yahoo Finance [Last Updated On: March 5th, 2020] [Originally Added On: March 5th, 2020]
- Relationship between histopathological features of aspirated thrombi and long-term left ventricular function in patients with ST-segment elevation... [Last Updated On: March 15th, 2020] [Originally Added On: March 15th, 2020]
- FierceMedTech Names BioVentrix as One of Its "Fierce 15" Companies of 2019 - Yahoo Finance [Last Updated On: March 15th, 2020] [Originally Added On: March 15th, 2020]
- Causes and Prevention of Ventricular Remodeling After MI ... [Last Updated On: March 16th, 2020] [Originally Added On: March 16th, 2020]
- Left Ventricular Remodelling - ECR Journal [Last Updated On: April 23rd, 2020] [Originally Added On: April 23rd, 2020]
- Cardiac Restoration Systems Market to Make Great Impact in Near Future by 2026 - The Canton Independent Sentinel [Last Updated On: June 12th, 2020] [Originally Added On: June 12th, 2020]
- Multi-Society Guidelines on the Use of Multimodality CV Imaging in Competitive Athletes - The Cardiology Advisor [Last Updated On: June 12th, 2020] [Originally Added On: June 12th, 2020]
- Chronic PDE5i Treatment Found to Improve Cardiac Remodeling in Men, but Not Women, With Diabetic Cardiomyopathy - Endocrinology Advisor [Last Updated On: June 12th, 2020] [Originally Added On: June 12th, 2020]
- Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Thoracic Society 2020... [Last Updated On: June 23rd, 2020] [Originally Added On: June 23rd, 2020]
- The Association of Cardio-Ankle Vascular Index (CAVI) with Biatrial Remodeling in Atrial Fibrillation - DocWire News [Last Updated On: September 3rd, 2020] [Originally Added On: September 3rd, 2020]
- Cardiac Dimensions Announces Australian Therapeutic Goods Administration's Approval of the Carillon System for the Treatment of Functional Mitral... [Last Updated On: September 3rd, 2020] [Originally Added On: September 3rd, 2020]
- Sep 4 2020 This Week in Cardiology - Medscape [Last Updated On: September 5th, 2020] [Originally Added On: September 5th, 2020]
- Emerging treatment helps reverse heart failure in some patients - Science Codex [Last Updated On: October 27th, 2020] [Originally Added On: October 27th, 2020]
- GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial - PRNewswire [Last Updated On: October 27th, 2020] [Originally Added On: October 27th, 2020]
- North America to Outshine the Global Slowdown in Cardiac Restoration Systems market between 2020 and 2030 - The Think Curiouser [Last Updated On: November 12th, 2020] [Originally Added On: November 12th, 2020]
- Age-Related Development of Cardiac Remodeling and Dysfunction in Young Black and White Adults: the Coronary Artery Risk Development in Young Adults... [Last Updated On: November 25th, 2020] [Originally Added On: November 25th, 2020]
- Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin - Science Advances [Last Updated On: January 13th, 2021] [Originally Added On: January 13th, 2021]
- Longer Survival Seen in Heart Failure Stabilized Via Cardiac Resynchronization Therapy - The Cardiology Advisor [Last Updated On: April 13th, 2021] [Originally Added On: April 13th, 2021]
- Cardiac Dimensions Welcomes Robert White to its Board of Directors - PRNewswire [Last Updated On: April 13th, 2021] [Originally Added On: April 13th, 2021]
- [Full text] SIRT1 is Required for Exercise-Induced Beneficial Effects on Myocardia | JIR - Dove Medical Press [Last Updated On: April 13th, 2021] [Originally Added On: April 13th, 2021]
- Role of Pyroptosis in Diabetes and Its Therapeutic Implications | JIR - Dove Medical Press [Last Updated On: May 25th, 2021] [Originally Added On: May 25th, 2021]
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press [Last Updated On: May 25th, 2021] [Originally Added On: May 25th, 2021]
- Are you at risk for sudden death, and can it be prevented? - Jamaica Observer [Last Updated On: May 25th, 2021] [Originally Added On: May 25th, 2021]
- Does a plant-based diet improve cardiac function? Here's the answer - Hindustan Times [Last Updated On: June 21st, 2021] [Originally Added On: June 21st, 2021]
- Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI - AJMC.com Managed Markets Network [Last Updated On: November 5th, 2021] [Originally Added On: November 5th, 2021]
- Higher BP, LV Changes Seen in Children Conceived by ART - Medscape [Last Updated On: November 5th, 2021] [Originally Added On: November 5th, 2021]
- Regional Heterogeneity in Determinants of Atrial Matrix Remodeling and Association with Atrial Fibrillation Vulnerability Post-Myocardial Infarction -... [Last Updated On: January 26th, 2022] [Originally Added On: January 26th, 2022]
- 4 promising heart failure therapies interventional cardiologists should keep an eye on - Cardiovascular Business [Last Updated On: May 7th, 2022] [Originally Added On: May 7th, 2022]
- LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - Yahoo Finance [Last Updated On: May 7th, 2022] [Originally Added On: May 7th, 2022]
- Ventricular structure and function in hypertensive patients | IJGM - Dove Medical Press [Last Updated On: May 7th, 2022] [Originally Added On: May 7th, 2022]
- Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction:... [Last Updated On: May 7th, 2022] [Originally Added On: May 7th, 2022]
- Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study - Business Wire [Last Updated On: September 12th, 2022] [Originally Added On: September 12th, 2022]